1. Home
  2. LCFY vs HOTH Comparison

LCFY vs HOTH Comparison

Compare LCFY & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Locafy Limited

LCFY

Locafy Limited

HOLD

Current Price

$4.35

Market Cap

8.3M

Sector

N/A

ML Signal

HOLD

Logo Hoth Therapeutics Inc.

HOTH

Hoth Therapeutics Inc.

HOLD

Current Price

$0.65

Market Cap

12.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCFY
HOTH
Founded
2009
2017
Country
Australia
United States
Employees
18
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
12.8M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
LCFY
HOTH
Price
$4.35
$0.65
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$5.00
AVG Volume (30 Days)
7.4K
395.0K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.69
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.50
$0.49
52 Week High
$13.98
$2.12

Technical Indicators

Market Signals
Indicator
LCFY
HOTH
Relative Strength Index (RSI) 52.79 38.59
Support Level $4.07 $0.49
Resistance Level $4.84 $0.80
Average True Range (ATR) 0.18 0.04
MACD -0.01 -0.00
Stochastic Oscillator 73.58 11.82

Price Performance

Historical Comparison
LCFY
HOTH

About LCFY Locafy Limited

Locafy Ltd is an Australian company currently focused on commercializing its Software as a Service (SaaS) online marketing technology (Technology), which prominently delivers a cost-effective location-based digital marketing solution for small businesses in the key markets of the USA, Australia and Canada. The company has two operating segments: Publishing and SEO Agency. The company derives the majority of its revenue from license subscription fees and advertising fees. Geographically, the maximum revenue is derived from North America.

About HOTH Hoth Therapeutics Inc.

Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA). Its current assets are focused in treating cancer, skin toxicities, Alzheimer's, and weight loss.

Share on Social Networks: